within Pharmacolibrary.Drugs.ATC.J;

model J05AB16
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0011749999999999998,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.045200000000000004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.048799999999999996,
    k12             = 67.8,
    k21             = 67.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AB16</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Remdesivir is a broad-spectrum antiviral medication that inhibits viral RNA-dependent RNA polymerase. It was originally developed for the treatment of Ebola virus, but is more widely used today for the treatment of COVID-19 in hospitalized patients. Remdesivir is approved or authorized in many countries as a treatment for COVID-19.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following single intravenous dose administration.</p><h4>References</h4><ol><li><p>Brooks, KM, et al., &amp; Momper, JD (2024). Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032. <i>The Journal of infectious diseases</i> 230(4) 878–888. DOI:<a href=&quot;https://doi.org/10.1093/infdis/jiae298&quot;>10.1093/infdis/jiae298</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38839047/&quot;>https://pubmed.ncbi.nlm.nih.gov/38839047</a></p></li><li><p>Walimbwa, SI, et al., &amp; Lamorde, M (2021). An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). <i>Trials</i> 22(1) 831–None. DOI:<a href=&quot;https://doi.org/10.1186/s13063-021-05752-1&quot;>10.1186/s13063-021-05752-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34814933/&quot;>https://pubmed.ncbi.nlm.nih.gov/34814933</a></p></li><li><p>Sise, ME, et al., &amp; McPhail, MJ (2024). Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 79(5) 1172–1181. DOI:<a href=&quot;https://doi.org/10.1093/cid/ciae333&quot;>10.1093/cid/ciae333</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38913574/&quot;>https://pubmed.ncbi.nlm.nih.gov/38913574</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AB16;
